Table 1.
Patient 1 | Patient 2 | Patient 3 | Patient 4 | |
---|---|---|---|---|
Age (years) | 26 | 63 | 76 | 82 |
Sex | F | F | M | M |
Diabetes type | Type 1 | Type 2 | Newly diagnosed type 2 | Type 2 |
COVID-19 severity | Mild | Moderate | Severe | Severe |
Need for oxygen support | Room air | Oxygen 4 L/min | Ventilator | High-flow oxygen |
Additional comorbidities | None | Ischemic CVA, HTN | HTN, NAFLD, CKD, hypothyroidism | HTN and dyslipidemia status post mechanical AVR, osteoporosis, past smoker |
Diabetes treatment | CSII | MDI | MDI | MDI |
Glucose management before CGM | ||||
Mean blood glucose tests per day | 4.7 | 2.8 | 3.75 | 3.0 |
Mean ± SD blood glucose (mg/dL) | 127 ± 33 | 382 ± 188 | 192 ± 79 | 183 ± 14 |
Glucose management with remote real-time CGM | ||||
Mean blood glucose tests per day | 2.3 | 1.5 | 1.8 | 2.1 |
Mean ± SD blood glucose (mg/dL) | 127 ± 32 | 200 ± 54 | 168 ± 63 | 145 ± 45 |
Time with transmitted data (%) | 96.3 | 72.3 | 90.8 | 97.2 |
TIR >250 mg/dL (%) | 0.0 | 13.2 | 13.7 | 1.7 |
TIR 180–250 mg/dL (%) | 5.7 | 56.7 | 29.0 | 14.2 |
TIR 110–180 mg/dL (%) | 60.4 | 30.0 | 32.7 | 64.2 |
TIR 70–110 mg/dL (%) | 33.1 | 0.1 | 23.9 | 12.6 |
TIR <70 mg/dL (%) | 0.8 | 0.0 | 0.7 | 5.6 |
TIR <54 mg/dL (%) | 0.0 | 0.0 | 0.0 | 1.7 |
AVR, aortic valve replacement; CSII, continuous subcutaneous insulin infusion; CVA, cerebrovascular accident; HTN, hypertension; MDI, multiple daily injections of insulin; NAFLD, nonalcoholic fatty liver disease; TIR, time in range.